Michael Lilly to Kallikreins
This is a "connection" page, showing publications Michael Lilly has written about Kallikreins.
Connection Strength
0.085
-
A phase II study of docetaxel plus lycopene in metastatic castrate resistant prostate cancer. Biomed Pharmacother. 2021 Nov; 143:112226.
Score: 0.044
-
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. Cancer Treat Res Commun. 2020; 24:100193.
Score: 0.041